Nepafenac

Last updated
Nepafenac
Nepafenac-2D-skeletal.svg
Clinical data
Trade names Nevanac, Ilevro, Amnac, others
AHFS/Drugs.com Monograph
MedlinePlus a606007
License data
Pregnancy
category
Routes of
administration 		Topical eye drops
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only) [2]
  • US: ℞-only
  • In general: ℞ (Prescription only)
Identifiers
  • 2-amino-3-benzoylbenzeneacetamide
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard 100.207.414 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C15H14N2O2
Molar mass 254.289 g·mol−1
3D model (JSmol)
  • O=C(c1cccc(c1N)CC(=O)N)c2ccccc2
  • InChI=1S/C15H14N2O2/c16-13(18)9-11-7-4-8-12(14(11)17)15(19)10-5-2-1-3-6-10/h1-8H,9,17H2,(H2,16,18) Yes check.svgY
  • Key:QEFAQIPZVLVERP-UHFFFAOYSA-N Yes check.svgY
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Nepafenac, sold under the brand name Nevanac among others, is a nonsteroidal anti-inflammatory drug (NSAID), usually sold as a prescription eye drop 0.1% solution (Nevanac) or 0.3% solution (Ilevro). It is used to treat pain and inflammation associated with cataract surgery. [3] Nepafenac is a prodrug of amfenac, an inhibitor of COX-1 and COX-2 activity. [4] [5]

Contents

Medical uses

Nepafenac is indicated for use in the treatment of pain and inflammation following cataract surgery. [3] [6] [7] [8]

In the European Union nepafenac is also indicated for the reduction in the risk of postoperative macular edema associated with cataract surgery in people with diabetes. [8]

Pharmacology

Mechanism of action

Nepafenac is an NSAID, thought to be a prodrug of amfenac after conversion by ocular tissue hydrolases after penetration via the cornea. [6] [7] Amfenac, like other NSAIDs, is thought to inhibit cyclooxygenase action. [6] [7]

Adverse events

Side effects include headache; runny nose; pain or pressure in the face; nausea; vomiting; and dry, itchy, sticky eyes. [9] Serious side effects include red or bloody eyes; foreign body sensation in the eye; sensitivity to light; decreased visual acuity; seeing specks or spots; teary eyes; or eye discharge or crusting. [9]

Regulatory

Nevanac

On February 25, 2005, Alcon filed a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for Nevanac 0.1%. [10] Results from the two trials referenced in the NDA (Phase 2/3 study C-02-53; Phase 3 study C-03-32) have not been published. [11] Study C-02-53 consisted of 228 patients across 10 centers in the United States. [12] Study C-03-32 consisted of 522 patients across 22 centers in the United States. [12] The efficacy results presented were confirmed in a study published in 2007. [13]

Nevanac was approved by the FDA on August 19, 2005, with application number 021–862. [14]

Ilevro

An NDA for Ilevro was filed on December 15, 2011. [15] In a one-month study, no new toxicities arose in the new formulation of nepafenac. [16] Safety and efficacy information was derived from the previous Nevanac application. [16] In June 2010, a confirmatory study began (Study C09055) consisting of over 2000 patients from 49 US sites and 37 European sites. [17] [18] A second phase 3 trial (Study C11003) was conducted in a population of 1,342 patients at 37 sites across the United States which failed to demonstrate superiority over Nevanac in an altered dosing regimen. [17]

Ilevro was approved by the FDA on October 16, 2012, with application number 203–491. [19]

Commercialization

Both Nevanac and Ilevro are manufactured and sold by Alcon, Inc. [6] [7] Alcon is currently a division of Novartis International AG, which is primarily based out of Switzerland. [20] Alcon, Inc. also holds locations in both Switzerland and the United States. [21] The company has gone through several name changes, from Alcon Laboratories, Inc. to Alcon Universal, Ltd., to Alcon, Inc. [21]

Nevanac entered the market in 2005 as a product of Alcon, at the time a subsidiary of Nestlé. [22] On April 6, 2008, Novartis agreed to purchase approximately 74 million shares of Alcon from Nestlé at $143.18 per share. [22] On January 4, 2010, Novartis agreed to purchase all remaining shares of Alcon from Nestlé, totalling 156 million shares or 77% of the shares in the company. [22] At the time of the purchase, a proposal for a merger under Swiss merger law was given to the Alcon board of directors. [22] The merger was agreed upon on December 15, 2010, making Alcon "the second largest division within Novartis." [22] The merger was completed on April 8, 2011. [23]

Ilevro was launched by Alcon on January 21, 2013. [24] In 2014 and 2015, net sales by Alcon grew, contributed to in part by the increased volume in sales of Ilevro. [25] [26] [27] That financial year, Novartis reported $18 billion in total financial debt. [25] That figure has grown steadily since. In 2016, Novartis reported a total debt of $23.8 billion, [28] up from the $21.9 billion reported in 2015 [27] and the $20.4 billion reported in 2014. [26] As of May 2017, Novartis is estimated to be worth $193.2 billion. [29]

On January 27, 2016, Alcon was moved to become a branch of the Innovative Medicines Division at Novartis. [28] Early in 2016, Alcon formed agreements with both TrueVision and PowerVision, and acquired Transcend Medical. [28] As of January 2017, Novartis is weighing options for Alcon in the business structure. [28]

Commercial risks

Alcon faced declining growth in 2016, having faced challenges in development and marketing of new products. [28]

Marketing

Novartis maintains a detailing unit geared toward health professionals consisting of over 3,000 employees within the United States and an additional 21,000 worldwide. [28] Novartis is also seeking to expand direct-to-consumer advertising and entrance into specialty product markets. [28] Novartis also notes the influence of position and preference on US Centers for Medicare & Medicaid formularies in expanding their market value. [28]

Nepafenac, Nevanac, and Ilevro are all absent from the 2016 Annual Report issued from Novartis. [28]

Intellectual property

There are currently[ when? ] seven U.S. patents filed that are directly associated with the modernized formulations of nepafenac, all stemming from Novartis. [30] There are three patents associated with Nevanac that are still[ when? ] active [31] and four associated with Ilevro. [32] The earliest patent related to the modern formulations of nepafenac was approved on June 11, 2002, after being filed in 1999, by Bahram Asgharian. [33] A patent was filed by Warren Wong, associated with Alcon, Inc. based out of Fort Worth, Texas, on December 2, 2005, for aqueous suspensions of nepafenac. [34] Another patent for a nepafenac-based drug was filed on May 8, 2006, by Geoffrey Owen, Amy Brooks, and Gustav Graff. [35] A patent was filed by Masood A. Chowhan and Huagang Chen on February 9, 2007, and approved on May 24, 2011, [36] followed closely by a patent filed by Warren Wong on September 23, 2010, and approved on December 6, 2011. [37] Masood A. Chowhan, Malay Ghosh, Bahram Asgharian, and Wesley Wehsin Han filed another patent on December 1, 2010, and approved on December 30, 2014. [38] The most recent[ when? ] patent was filed by Masood A. Chowhan, Malay Ghosh, Bahram Asgharian, and Wesley Weshin Han on November 12, 2014, and approved on May 30, 2017. [39] These patents are in effect until dates ranging between July 17, 2018, and March 31, 2032. [32]

Novartis also maintains patents on nepafenac in 26 countries outside the United States. [40]

Related Research Articles

<span class="mw-page-title-main">Ibuprofen</span> Medication used for treating pain, fever, and inflammation

Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that is used to relieve pain, fever, and inflammation. This includes painful menstrual periods, migraines, and rheumatoid arthritis. It may also be used to close a patent ductus arteriosus in a premature baby. It can be used orally or intravenously. It typically begins working within an hour.

<span class="mw-page-title-main">Novartis</span> Swiss-American multinational pharmaceutical corporation

Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Consistently ranked in the global top five, Novartis is one of the largest pharmaceutical companies in the world and was the fourth largest by revenue in 2022.

<span class="mw-page-title-main">Lumiracoxib</span> Cox-2 inhibitor anti-inflammatory drug

Lumiracoxib is a COX-2 selective inhibitor nonsteroidal anti-inflammatory drug.

<span class="mw-page-title-main">Oxaprozin</span> Chemical compound

Oxaprozin, also known as oxaprozinum, is a nonsteroidal anti-inflammatory drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis. Chemically, it is a propionic acid derivative. Safety and efficacy has been established in children over 6 years with juvenile rheumatoid arthritis only, and there is an increased risk of adverse reactions in the elderly population.

<span class="mw-page-title-main">Meloxicam</span> Nonsteroidal anti-inflammatory drug (NSAID)

Meloxicam, sold under the brand name Mobic among others, is a nonsteroidal anti-inflammatory medication (NSAID) used to treat pain and inflammation in rheumatic diseases and osteoarthritis. It is used by mouth or by injection into a vein. It is recommended that it be used for as short a period as possible and at a low dose.

<span class="mw-page-title-main">Ketorolac</span> Nonsteroidal anti-inflammatory drug (NSAID; analgesic)

Ketorolac, sold under the brand names Toradol, and Biorolac among others, is a nonsteroidal anti-inflammatory drug (NSAID) used to treat pain. Specifically it is recommended for moderate to severe pain. Recommended duration of treatment is less than six days, and in Switzerland not more than two days. It is used by mouth, by nose, by injection into a vein or muscle, and as eye drops. Effects begin within an hour and last for up to eight hours.

<span class="mw-page-title-main">Alcon</span> American Based Eye Pharmaceutical Company

Alcon is a Swiss-American pharmaceutical and medical device company specializing in eye care products. It is headquartered in Geneva, Switzerland and has a major presence in Fort Worth, Texas, United States, where it employs about 4,500 people.

<span class="mw-page-title-main">Moxifloxacin</span> Antibiotic

Moxifloxacin is an antibiotic, used to treat bacterial infections, including pneumonia, conjunctivitis, endocarditis, tuberculosis, and sinusitis. It can be given by mouth, by injection into a vein, and as an eye drop.

<span class="mw-page-title-main">Clindamycin/benzoyl peroxide</span> Type of medication

Clindamycin/benzoyl peroxide is a topical gel used for the treatment of acne. It is a fixed-dose combination of clindamycin, as the phosphate, an antibiotic, and benzoyl peroxide, an antiseptic.

<span class="mw-page-title-main">Ciprofloxacin/dexamethasone</span> Pharmaceutical product

Ciprofloxacin/dexamethasone (Ciprodex) is an antibiotic/steroid combination medication. It contains the synthetic broad-spectrum antibacterial agent, ciprofloxacin hydrochloride (0.3%), combined with the anti-inflammatory corticosteroid, dexamethasone (0.1%), in a sterile, preserved suspension for otic use.

<span class="mw-page-title-main">Flurbiprofen</span> Chemical compound

Flurbiprofen is a member of the phenylalkanoic acid derivative family of nonsteroidal anti-inflammatory drugs (NSAIDs). It is primarily indicated as a pre-operative anti-miotic as well as orally for arthritis or dental pain. Side effects are analogous to those of ibuprofen.

<span class="mw-page-title-main">Anecortave acetate</span> Chemical compound

Anecortave (rINN) is a novel angiogenesis inhibitor used in the treatment of the exudative (wet) form of age-related macular degeneration. Although similar in chemical structure to the corticosteroid hydrocortisone acetate, it possesses no glucocorticoid activity. If it is approved, it will be marketed by Alcon as anecortave acetate for depot suspension under the trade name Retaane. No development has been reported since 2010.

<span class="mw-page-title-main">Bromfenac</span> Chemical compound

Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) marketed in the US as an ophthalmic solution by ISTA Pharmaceuticals for short-term, local use. Prolensa and Bromday are the once-daily formulation of bromfenac, while Xibrom was approved for twice-daily administration. In the European Union, the brand name is Yellox. Bromfenac is indicated for the treatment of ocular inflammation and pain after cataract surgery.

<span class="mw-page-title-main">Besifloxacin</span> Chemical compound

Besifloxacin (INN/USAN) is a fourth-generation fluoroquinolone antibiotic. The marketed compound is besifloxacin hydrochloride. It was developed by SSP Co. Ltd., Japan, and designated SS734. SSP licensed U.S. and European rights to SS734 for ophthalmic use to InSite Vision Incorporated in 2000. InSite Vision developed an eye drop formulation (ISV-403) and conducted preliminary clinical trials before selling the product and all rights to Bausch & Lomb in 2003.

<span class="mw-page-title-main">Hydrocodone/ibuprofen</span> Combination drug

Hydrocodone/ibuprofen (INNs), sold under the brand name Vicoprofen, is a fixed-dose combination analgesic medication used in short-term therapy to relieve severe pain. Vicoprofen combines the analgesic and antitussive properties of hydrocodone with the analgesic, anti-inflammatory, and antipyretic properties of ibuprofen. In contrast to hydrocodone/acetaminophen combination analgesics such as Vicodin, this hydrocodone/ibuprofen avoids some of the liver toxicity which may occur from acetaminophen, but still presents significant dangers in hydrocodone overdose, namely respiratory depression. Vicoprofen is supplied in a fixed dose combination tablet which contains hydrocodone bitartrate, USP 7.5 mg with ibuprofen, USP 200 mg. Additional strengths of generic Vicoprofen are now available, in combinations of 5 mg/200 mg and 10 mg/200 mg respectively.

Aliskiren/amlodipine/hydrochlorothiazide, sold under the brand name Amturnide, is a fixed-dose combination medication that is used to treat high blood pressure. It contains aliskiren, amlodipine, and hydrochlorothiazide. It is taken by mouth.

<span class="mw-page-title-main">Pasireotide</span> Pharmaceutical drug

Pasireotide, sold under the brand name Signifor, is an orphan drug approved in the United States and the European Union for the treatment of Cushing's disease in patients who fail or are ineligible for surgical therapy. It was developed by Novartis. Pasireotide is a somatostatin analog with a 40-fold increased affinity to somatostatin receptor 5 compared to other somatostatin analogs.

<span class="mw-page-title-main">Secukinumab</span> Monoclonal antibody against IL-17

Secukinumab, sold under the brand name Cosentyx among others, is a human IgG1κ monoclonal antibody used for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis. It binds to the protein interleukin (IL)-17A and is marketed by Novartis.

<span class="mw-page-title-main">Apixaban</span> Anticoagulant medication

Apixaban, sold under the brand name Eliquis, is an anticoagulant medication used to treat and prevent blood clots and to prevent stroke in people with nonvalvular atrial fibrillation through directly inhibiting factor Xa. Specifically, it is used to prevent blood clots following hip or knee replacement and in those with a history of prior clots. It is used as an alternative to warfarin and does not require monitoring by blood tests or dietary restrictions. It is taken by mouth.

<span class="mw-page-title-main">Adrenocorticotropic hormone (medication)</span> Chemical compound

Adrenocorticotropic hormone is used as a medication and as diagnostic agent in the ACTH stimulation test.

References

  1. ↑ "Nepafenac ophthalmic Use During Pregnancy". Drugs.com. 6 June 2019. Retrieved 13 September 2020.
  2. ↑ "Prescription medicines: registration of new chemical entities in Australia, 2015". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.
  3. 1 2 Nepafenac Monograph
  4. ↑ Drugbank: Nepafenac
  5. ↑ Zanetti FR, Fulco EA, Chaves FR, da Costa Pinto AP, Arieta CE, Lira RP (July 2012). "Effect of preoperative use of topical prednisolone acetate, ketorolac tromethamine, nepafenac and placebo, on the maintenance of intraoperative mydriasis during cataract surgery: a randomized trial". Indian Journal of Ophthalmology. 60 (4): 277–81. doi: 10.4103/0301-4738.98705 . PMC   3442462 . PMID   22824596.
  6. 1 2 3 4 "Nevanac- nepafenac suspension/ drops". DailyMed. 9 September 2019. Retrieved 6 July 2020.
  7. 1 2 3 4 "Ilevro- nepafenac suspension". DailyMed. 9 September 2019. Retrieved 6 July 2020.
  8. 1 2 "Nevanac EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 6 July 2020.
  9. 1 2 "Nepafenac Ophthalmic". MedlinePlus. U.S. National Library of Medicine. Retrieved October 31, 2017.
  10. ↑ "Nevanac Approval Package" (PDF). U.S. Food and Drug Administration (FDA). Retrieved October 31, 2017.
  11. ↑ Gaynes BI, Onyekwuluje A (June 2008). "Topical ophthalmic NSAIDs: a discussion with focus on nepafenac ophthalmic suspension". Clinical Ophthalmology. 2 (2): 355–68. doi: 10.2147/opth.s1067 . PMC   2693998 . PMID   19668727.
  12. 1 2 "Nevanac Statistical Review" (PDF). U.S. Food and Drug Administration (FDA). Retrieved October 31, 2017.
  13. ↑ Lane SS, Modi SS, Lehmann RP, Holland EJ (January 2007). "Nepafenac ophthalmic suspension 0.1% for the prevention and treatment of ocular inflammation associated with cataract surgery". Journal of Cataract and Refractive Surgery. 33 (1): 53–8. doi:10.1016/j.jcrs.2006.08.043. PMID   17189793. S2CID   38881826.
  14. ↑ "Drug Approval Package: Nevanac (Nepafenac) Ophthalmic Suspension NDA #021862". U.S. Food and Drug Administration (FDA). January 6, 2005. Retrieved October 27, 2017.
  15. ↑ "Ilevro Approval Package" (PDF). U.S. Food and Drug Administration (FDA). Retrieved October 31, 2017.
  16. 1 2 "203491 Pharmacology Review" (PDF). U.S. Food and Drug Administration (FDA). Retrieved October 31, 2017.
  17. 1 2 "Ilevro Statistical Review" (PDF). U.S. Food and Drug Administration (FDA). Retrieved October 31, 2017.
  18. ↑ "Confirmatory Study Nepafenac 0.3%". ClinicalTrials.gov. U.S. National Library of Medicine. 29 November 2012. Retrieved October 31, 2017.
  19. ↑ "Drug Approval Package: Nepafenac Ophthalmic Suspension, 0.3% NDA #203491". U.S. Food and Drug Administration (FDA). April 8, 2013. Retrieved October 27, 2017.
  20. ↑ "About Us". Novartis. Retrieved October 27, 2017.
  21. 1 2 "Nevanac Administrative Documents and Correspondence" (PDF). U.S. Food and Drug Administration (FDA). Retrieved October 27, 2017.
  22. 1 2 3 4 5 "Alcon Annual Report 2010" (PDF). SEC EDGAR. United States Securities and Exchange Commission. Retrieved October 30, 2017.
  23. ↑ "Alcon Form 15". SEC EDGAR. United States Securities and Exchange Commission. Retrieved October 30, 2017.
  24. ↑ "Alcon Launches ILEVRO™ (nepafenac ophthalmic suspension) 0.3%, a New Non-Steroidal Anti-Inflammatory Drug, for the Treatment of Pain and Inflammation Associated with Cataract Surgery". Alcon. Archived from the original on December 15, 2018. Retrieved October 30, 2017.
  25. 1 2 "Form 20-F". SEC EDGAR. United States Securities and Exchange Commission. Retrieved October 30, 2017.
  26. 1 2 "Form 20-F". SEC EDGAR. United States Securities and Exchange Commission. Retrieved October 30, 2017.
  27. 1 2 "Form 20F". SEC EDGAR. United States Securities and Exchange Commission. Retrieved October 30, 2017.
  28. 1 2 3 4 5 6 7 8 9 "Form 20-F". SEC EDGAR. United States Securities and Exchange Commission. Retrieved October 31, 2017.
  29. ↑ "Novartis on the Forbes Top Multinational Performers List". Forbes. Retrieved October 31, 2017.
  30. ↑ "Nepafenac". U.S. Patents. PharmaCompass. Retrieved October 30, 2017.
  31. ↑ "Generic Nevanac Availability". Drugs.com. Retrieved October 31, 2017.
  32. 1 2 "Generic Ilevro Availability". Drugs.com. Retrieved October 31, 2017.
  33. ↑ "United States Patent Application: 6403609". United States Patent and Trademark Office. Retrieved October 31, 2017.
  34. ↑ "United States Patent Application: 0060122277". United States Patent and Trademark Office. Retrieved October 30, 2017.
  35. ↑ "United States Patent Application: 0060257487". United States Patent and Trademark Office. Retrieved October 27, 2017.
  36. ↑ "United States Patent: 7947295". United States Patent and Trademark Office. Retrieved October 31, 2017.
  37. ↑ "United States Patent: 8071648". United States Patent and Trademark Office. Retrieved October 31, 2017.
  38. ↑ "United States Patent: 8921337". United States Patent and Trademark Office. Retrieved October 31, 2017.
  39. ↑ "United States Patent: 9662398". United States Patent and Trademark Office. Retrieved October 31, 2017.
  40. ↑ "Nepafenac - Generic Drug Details". DrugPatentWatch. thinkBiotech LLC. Retrieved October 31, 2017.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.